Apr 25 2021 Read 2 Times
Setsuro Tech, a Japanese biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, has signed a non-exclusive license for access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan.
“The versatility and programmability of Cas9 has enabled the CRISPR/Cas9 technology to become a revolutionary approach in biological research,” said Eric Rhodes, CEO of Dublin-based ERS Genomics. “We are pleased to support Setsuro Tech with this license agreement so that they are able to continue providing supportive tools and services for research activities.”
“Our technology enables us to provide researchers with genome-edited models quickly and at relatively low cost,” commented Shinichiro Takezawa, CEO, Setsuro Tech, Tokushima. “The license from ERS expands our portfolio and having access to advanced technologies such as CRISPR/Cas9 will allow us to continue our high-quality offerings that combine CRISPR/Cas9 with our patent-pending technologies.”